Table 2.
Characteristics of magnesium sulfate boluses and infusion in treatment and control groups (n = 135).
| Variables | Treatment group (n = 27) | Control group (n = 108) | p-value |
|---|---|---|---|
| Number (%) or Median (IQR) | |||
| Magnesium sulfate boluses | |||
| Received magnesium boluses | 27 (100.0) | 88 (81.5) | 0.01a |
| Number of magnesium boluses administered | 3 (2–4) | 1 (1–2) | <0.01b |
| Cumulative bolus dose (mg) | 4,000.0 (2,750.0–6,000.0) | 2,000.0 (1,400.0–2,295.0) | <0.01b |
| Cumulative bolus dose (mg/kg) | 93.8 (68.8–158.3) | 49.6 (34.6–87.1) | <0.01b |
| Magnesium sulfate infusions | |||
| Rate to achieve the target serum concentration (mg/kg/h)c | 19.9 (15.8–22.4) | – | – |
| Duration (hours) | 28 (17–58.5) | – | – |
| Number of infusion rates increased | 2 (0–3) | – | – |
| Number of infusion rates decreased | 0 (0–1) | – | – |
| Cumulative infusion dose (mg) | 19,939.0 (9,360.0–56,056.0) | – | – |
| Cumulative infusion dose (mg/kg) | 560.0 (240.0–1,594.0) | – | – |
IQR, Interquartile range.
a
Fisher's exact test.
b
Wilcoxon two-sample test.
c
Target magnesium serum concentration was 4–6 mg/dL.